The earnings call provided a mix of stabilization achievements and challenges. While the company successfully reduced debt and inventory and saw growth in the Americas D2C market, overall revenue and gross margins declined, particularly in the EMEA region. The sentiment is balanced with significant progress on strategic objectives but offset by declines in key areas.

Company Guidance

In the FY '25 results presentation, the company emphasized its successful stabilization efforts, reporting on several key metrics and achievements. The Americas D2C segment returned to growth in the second half, while overall revenue was down 8% to GBP 805 million on a constant currency basis, driven by a 9% decrease in total pairs sold. The company achieved GBP 25 million in annualized cost savings and reduced inventory by GBP 67 million, surpassing their target of GBP 40 million, leading to a GBP 95 million reduction in net debt. Despite gross margin rates declining due to product mix changes, the adjusted EBIT was GBP 67.1 million, and adjusted PBT was GBP 40.3 million, both slightly ahead of consensus. The balance sheet was strengthened with net bank debt reduced by GBP 83.4 million to GBP 94.1 million, and cash flow was bolstered by GBP 108 million from operations. The results reflect disciplined cost management and strategic inventory reductions, setting the stage for future growth and stability.

Americas D2C Growth

The Americas Direct-to-Consumer (D2C) market returned to growth in the second half of FY '25, setting momentum for FY '26 despite smaller D2C months.

Significant Debt and Inventory Reduction

The company reduced net debt by GBP 95 million and inventory by GBP 67 million, surpassing the original goal of GBP 40 million.

Cost Savings and Balance Sheet Strengthening

Implemented a cost action plan resulting in GBP 25 million of annualized savings and a stronger balance sheet.

Positive APAC Performance

Continued strong year-on-year growth in Direct-to-Consumer sales in Japan, South Korea, and China, with South Korea noted for particular strength in Q4.

Dr. Martens Plc (GB:DOCS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:DOCS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 27, 2025	2026 (Q2)	-0.01 / -	-0.013	―	―	―
Jun 05, 2025	2025 (Q4)	0.03 / 0.04	0.051	-29.41% (-0.01)	―	―
Nov 28, 2024	2025 (Q2)	-0.02 / -0.01	0.019	-168.42% (-0.03)	―	―
May 30, 2024	2024 (Q4)	0.05 / 0.05	0.084	-39.29% (-0.03)	―	―
Nov 30, 2023	2024 (Q2)	0.02 / 0.02	0.045	-57.78% (-0.03)	―	―
Jun 01, 2023	2023 (Q4)	0.10 / 0.08	0.132	-36.36% (-0.05)	―	―
Nov 24, 2022	2023 (Q2)	0.05 / 0.04	0.048	-6.25% (>-0.01)	―	―
Jun 01, 2022	2022 (Q4)	0.10 / 0.13	0.082	60.98% (+0.05)	―	―
Dec 09, 2021	2022 (Q2)	0.05 / 0.05	0.084	-42.86% (-0.04)	―	―
Jun 17, 2021	2021 (Q4)	- / 0.08	0.164	-50.00% (-0.08)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:DOCS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jun 05, 2025	58.85p	74.02p	+25.78%
Nov 28, 2024	55.98p	63.58p	+13.58%
May 30, 2024	80.16p	80.25p	+0.11%
Nov 30, 2023	107.72p	84.63p	-21.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Dr. Martens Plc (GB:DOCS) report earnings?

Dr. Martens Plc (GB:DOCS) is schdueled to report earning on Nov 27, 2025, Before Open (Confirmed).

What is Dr. Martens Plc (GB:DOCS) earnings time?

Dr. Martens Plc (GB:DOCS) earnings time is at Nov 27, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Dr. Martens Plc stock?

The P/E ratio of Dr. Martens Plc is N/A.

What is GB:DOCS EPS forecast?

GB:DOCS EPS forecast for the fiscal quarter 2026 (Q2) is -0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing